Cancer cells often overexpress CD47, which triggers the macrophage receptor SIRPα to elude anti-tumor immunity. We found that CD47 also suppresses phagocytosis by masking a pro-phagocytic ligand, SLAMF7, on tumor cells. We generated a first-in-class SLAMF7 antibody, which dissociated the CD47–SLAMF7 cis interaction, enabling anti-tumor immunity during SIRPα blockade.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Liu, Y. et al. Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct. Target Ther. 8, 104 (2023). A review article that presents phagocytosis checkpoints as potential new targets for cancer immunotherapy.
Veillette, A. & Chen, J. SIRPα-CD47 immune checkpoint blockade in anticancer therapy. Trends Immunol. 39, 173–184 (2018). A review article that describes the SIRPα–CD47 immune checkpoint in cancer immunotherapy.
Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018). This paper reports the phase 1/2 clinical trial of CD47 antibody Hu5F9-G4 in non-Hodgkin’s lymphoma.
Chen, J. et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature 544, 493–497 (2017). This paper reports that SLAMF7 is a pro-phagocytotic receptor controlled by CD47 on macrophages.
Lu, Y. et al. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nat. Nanotechnol. 17, 1332–1341 (2022). This paper reports the generation of nanoconjugates containing SLAMF7 to decorate SLAMF7-negative solid cancer cells and broaden the scope of cancer types susceptible to CD47-based anti-cancer therapy.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Tang, Z. et al. CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress anti-tumor immunity. Nat. Immunol. https://doi.org/10.1038/s41590-023-01671-2 (2023).
Rights and permissions
About this article
Cite this article
Combining a first-in-class SLAMF7 antibody with SIRPα blockade for anti-tumor immunity. Nat Immunol 24, 1978–1979 (2023). https://doi.org/10.1038/s41590-023-01673-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-023-01673-0
